Glaxosmithkline Pharmaceuticals Moat Analysis: Score & Risks
Glaxosmithkline Pharmaceuticals Ltd.
A first-pass moat teardown of Glaxosmithkline Pharmaceuticals Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence.
Glaxosmithkline Pharmaceuticals Ltd. scores 5.01 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“The warehousing and distribution network comprising of more than 30 contract manufacturing facilities, 26 warehouses and 6,000 stockists continued to provide high levels of customer service on time.”
“Gross margins have improved both on pricing side, as well as better pricing on the raw materials.”
“Your Company has a strong portfolio of flagship brands, including Augmentin, Calpol, Ceftum, T-Bact, Betnovate, Neosporin, Tenovate, Varilix, Boostrix, Infanrix Hexa, Havrix and CobadexCZS which hold leading positions in their respective categories in the Indian pharmaceutical market.”
“Your Company has long-term loan licenses with various Contract Manufacturing Organisations (CMOs) that should help it tide over such unpredictable situations with minimum impact.”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 509 Indian companies we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion